X
XWPharma
Neuroscience biotech developing novel therapeutics for sleep, neuropsych, and other underserved CNS disorders
About XWPharma
XWPharma is a clinical-stage biopharmaceutical company focused on discovering and developing best-in-class novel therapeutics aimed at alleviating the suffering of patients with neurodegenerative diseases and psychiatric disorders. The company leverages its proprietary platform chemistry to create time-regulated neurobiological treatments. XWPharma primarily serves patients who suffer from conditions such as excessive daytime sleepiness, narcolepsy, and chronic pain, which are often associated with neurodegenerative diseases and psychiatric disorders. Operating in the biopharmaceutical market, the company follows a business model that involves extensive research and development (R&D), clinical trials, and eventual commercialization of its therapeutic products. Revenue is generated through the successful approval and sale of these therapeutics, as well as potential partnerships and licensing agreements with other pharmaceutical companies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- San Francisco, United States
- Employees
- 25
- Open positions
- None listed
- Dealroom signal
- 82.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Sep 2020 | $40M | $160M | Panacea Venture | — |
| SERIES BOther financing | Sep 2017 | $18M | $70M | WI Harper Group · Element Capital Management · Kleiner Perkins | — |
Growth signals
Latest recorded traffic for XWPharma is 260 monthly website visits, down 80% over the last three months. XWPharma's team grew 47.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
WI Harper Group
Element Capital Management
Kleiner Perkins
Series B and later1 investor entered at this stage
Panacea Venture
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about XWPharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See XWPharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.